Medicine Recommendations

LSCMMG

Black

BwD

Black

Black

Black

Black

Black

Black

Black

Black

Albiglutide

Date Posted: 01 - Jul - 2016

BNF chapter: Endocrine system

Expand/Collapse

Treatment of type 2 diabetes mellitus in adults to improve glycaemic control

Green

Green

Green

Green

Green

Green

Green

Green

Green

Alendronic Acid

Date Posted: 01 - Sep - 2017

BNF chapter: Endocrine system

Expand/Collapse

Osteoporosis (NICE TA464)

NICE TA464 - Bisphosphonates for treating osteoporosis - This guidance partially updates NICE TA 160 -Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women and NICE TA161 - Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures

Green

Green

Green

Green

Green

Green

Green

Green

Green

Alogliptin

Date Posted: 01 - Feb - 2018

BNF chapter: Endocrine system

Expand/Collapse

Type 2 diabetes

Black

Black

Black

Black

Black

Black

Black

Black

Black

Bazedoxifene / Conjugated Oestrogen

Date Posted: 01 - Dec - 2016

BNF chapter: Endocrine system

Expand/Collapse

Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate

Green

Green

Green

Green

Green

Green

Green

Green

Green

Biphasic Insulin (human)

Date Posted: 01 - Feb - 2018

BNF chapter: Endocrine system

Expand/Collapse

Type 1 and type 2 diabetes mellitus

Green

Green

Green

Green

Green

Green

Green

Green

Green

Biphasic insulin (Short-acting analogues)

Date Posted: 01 - Feb - 2018

BNF chapter: Endocrine system

Expand/Collapse

Type 1 and type 2 diabetes mellitus

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Pending

Cabergoline

Date Posted: 01 - Oct - 2014

BNF chapter: Endocrine system

Expand/Collapse

Hyperprolactinaemia

Red

Red

Red

Red

Red

Red

Red

Red

Red

Calcitonin injection

Date Posted: 01 - May - 2013

BNF chapter: Endocrine system

Expand/Collapse

Hypercalcaemia

Red

Red

Red

Red

Red

Red

Red

Red

Pending

Calcitonin injection

Date Posted: 01 - Oct - 2014

BNF chapter: Endocrine system

Expand/Collapse

Prevention of sudden bone loss due to sudden immobility

Green

Pending

Green

Green

Pending

Green

Green

Pending

Pending

Canagliflozin

Date Posted: 01 - Jun - 2014

BNF chapter: Endocrine system

Expand/Collapse

In combination therapy for treating type 2 diabetes (NICE TA315)

NICE TA315 - Canagliflozin in combination therapy for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Suitable for initiation in primary care in line with NICE restrictions (see background paragraph)

Green

Green

Green

Green

Green

Green

Green

Green

Green

Canagliflozin

Date Posted: 01 - Jun - 2016

BNF chapter: Endocrine system

Expand/Collapse

Monotherapy for treating type 2 diabetes (NICE TA390)

NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Red

Red

Red

Red

Red

Red

Red

Red

Red

Clomifene

Date Posted: 01 - Nov - 2013

BNF chapter: Endocrine system

Expand/Collapse

Anovulatory infertility

LSCMMG

Green (R)(Restricted)

BwD

Green (R)(Restricted)

BP

Green (R)(Restricted)

CSR

Green (R)(Restricted)

EL

Green (R)(Restricted)

FW

Green (R)(Restricted)

GP

Green (R)(Restricted)

MB

Green (R)(Restricted)

WL

Green (R)(Restricted)

Clonidine 25 mcg tablets

Date Posted: 09 - Jul - 2021

BNF chapter: Endocrine system

Expand/Collapse

Vasomotor symptoms (VMS) associated with menopause

Black

Black

Black

Black

Black

Black

Black

Black

Black

Compounded Thyroid Hormones

Date Posted: 01 - Oct - 2019

BNF chapter: Endocrine system

Hypothyroidism

Green

Green

Green

Green

Green

Green

Green

Green

Green

Dapagliflozin

Date Posted: 01 - Dec - 2016

BNF chapter: Endocrine system

Expand/Collapse

Triple therapy for treating type 2 diabetes (NICE TA418)

NICE TA418 - Dapagliflozin in triple therapy for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Green

Green

Green

Green

Green

Green

Green

Green

Green

Dapagliflozin

Date Posted: 19 - Apr - 2022

BNF chapter: Endocrine system

Expand/Collapse

Chronic kidney disease (NICE TA775)

NICE TA775 - Dapagliflozin for treating chronic kidney disease

LSCMMG

Green (R)(Restricted)

BwD

Green

BP

Green (R)(Restricted)

CSR

Green (R)(Restricted)

EL

Green

FW

Green (R)(Restricted)

GP

Green (R)(Restricted)

MB

Green

WL

Green (R)(Restricted)

Dapagliflozin

Date Posted: 01 - Dec - 2016

BNF chapter: Endocrine system

Expand/Collapse

In combination therapy for treating type 2 diabetes (NICE TA288)

NICE TA288 - Dapagliflozin in combination therapy for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Dapagliflozin

Date Posted: 20 - Jul - 2023

BNF chapter: Endocrine system

Expand/Collapse

Treating chronic heart failure with preserved or mildly reduced ejection fraction (NICE TA902)

NICE TA 902 - Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction

Green

Green

Green

Green

Green

Green

Green

Green

Green

Dapagliflozin

Date Posted: 01 - Jun - 2016

BNF chapter: Endocrine system

Expand/Collapse

Monotherapy for treating type 2 diabetes (NICE TA390)

NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Pending

Pending

Deflazacort

Date Posted: 01 - Oct - 2014

BNF chapter: Endocrine system

Expand/Collapse

Breadcrumb

Medicine Recommendations

Treatment of type 2 diabetes mellitus in adults to improve glycaemic control

Osteoporosis (NICE TA464)

Type 2 diabetes

Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate

Type 1 and type 2 diabetes mellitus

Type 1 and type 2 diabetes mellitus

Hyperprolactinaemia

Hypercalcaemia

Prevention of sudden bone loss due to sudden immobility

In combination therapy for treating type 2 diabetes (NICE TA315)

Suitable for initiation in primary care in line with NICE restrictions (see background paragraph)

Monotherapy for treating type 2 diabetes (NICE TA390)

Anovulatory infertility

Triple therapy for treating type 2 diabetes (NICE TA418)

In combination therapy for treating type 2 diabetes (NICE TA288)

Monotherapy for treating type 2 diabetes (NICE TA390)

Suppression of inflammatory and allergic disorders